Ironwood Pharmaceuticals (IRWD) FCF Margin (2010 - 2026)

Ironwood Pharmaceuticals has disclosed FCF Margin across 17 years of filings, most recently posting 4.81% for Q1 2026.

• FCF Margin for Q1 2026 came in at 4.81%, down 4362.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 31.04% (up 636.0% YoY), and the FY2025 annual result was 42.89%, up 1346.0% from the prior year.
• FCF Margin came in at 4.81% for Q1 2026 at Ironwood Pharmaceuticals, down from 156.31% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 156.31% in Q4 2025 to a low of 17.68% in Q2 2025.
• The 5-year median for FCF Margin is 38.98% (2025), against an average of 46.38%.
• Peak annual rise in FCF Margin reached 13951 bps in 2025, while the deepest fall reached 5307 bps in 2025.
• Ironwood Pharmaceuticals' FCF Margin stood at 73.89% in 2022, then sank by 59 bps to 30.3% in 2023, then plunged by 45 bps to 16.8% in 2024, then surged by 830 bps to 156.31% in 2025, then plunged by 97 bps to 4.81% in 2026.
• The last three FCF Margin figures came in at 4.81% (Q1 2026), 156.31% (Q4 2025), and 38.98% (Q3 2025), per Business Quant data.